Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneo (Q72628928)
Jump to navigation
Jump to search
scientific article published on 01 August 1993
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneo |
scientific article published on 01 August 1993 |
Statements
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy (English)
P Lissoni
S Barni
G Tancini
F Brivio
P Cardellini
M Vaghi
V Fossati
1 August 1993